IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Adjourns Voting for Proposals Three and Four from Annual Meeting of Shareholders

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has adjourned the voting for proposals three and four from its notice of annual meeting of shareholders, dated October 5, 2017. Proposal three seeks approval for the grant of 1.9 million shares of common stock, to be granted from time to time to the company’s current and new employees, advisors, directors and consultants by the board of directors. Proposal four seeks approval for the issuance of up to two million shares of the company’s common stock to Bricoleur Partners, L.P. Voting on these two proposals will now be adjourned to December 29, 2017, allowing IGC stockholders additional time to vote. Per the update, stockholders who have not yet voted can do so before December 29, 2017, at 11:59 pm EST by visiting www.ProxyVote.com, calling 800-454-8683 or returning a properly executed proxy card to InvestorCom.

To view the full press release, visit http://nnw.fm/HwZ5A

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us